Biomarker-based Early Anti-inflammatory Therapy for severe COVID-19

Biomarker-based Early Anti-inflammatory Therapy for severe COVID-19 - BEAT-COVID-1

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

NL-OMON

Registry ID

NL-OMON55200

Enrollment

275

Registered

2020-04-24

Start date

2020-04-24

Completion date

Unknown

Last updated

2024-04-15

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Coronavirus infection COVID-19

Interventions

None listed

Eligibility

Age

18 Years to 99 Years

Inclusion criteria

Inclusion criteria: hospitalized patients - Hospitalized patient with PCR confirmed COVID-19 infection - Eighteen years or older healthy volunteers - Not-hospitalized - Sixty years or older - Sars-CoV-2 serology negative mild infection - Positive SARS-CoV-2 PCR test from the GGD - No or limited symptoms of a viral airway infection (fever, cough, dyspnea, rhinorroea, myalgia, anosmia) at the time of inclusion - Age 18 years or older

Exclusion criteria

Exclusion criteria: Patients and healthy controls - Not able to give consent by the healthy volunteer, or the patient or patients representative Healthy controls - Symptoms of viral airway infection (e.g. fever, cough, rhinorroea, dyspnea) at screening or inclusion Group of infected individuals with little or no symptoms: - Having received vaccination against SARS-CoV-2 or previous confirmed infection with SARS-CoV-2. - Not being able to come to LUMC by own transportation to donate samples.

Design outcomes

Primary

Measure	Time frame
The main endpoint is the identification of pro-inflammatory biomarkers in the development of acute severe lung injury and multi-organ failure in infection with SARS-CoV-2	—

Secondary

Measure	Time frame
See protocol section 8.1.2 Secondary study parameters/endpoints	—

Countries

Netherlands

Outcome results